Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian
clinical-stage immune-oncology company, today announces the release of new data
describing how LTX-315 treatment activates specific immune cells that are
critical for a proper priming of tumor-specific T cells. 

The data will be presented as a poster at the Society for Immunotherapy of
CancerŽs 37th Annual Meeting (SITC 2022) in Boston, USA. 

The poster entitled "Molecular mechanisms of DC activation by melanoma cells
responding to LTX-315" describes how dendritic cells (DCs) can be activated by
LTX-315 through several distinct pathways. DCs are antigen-presenting cells
capable of tumor-antigen uptake, processing, and presentation to T cells. Once
activated, DCs migrate from tumor to the lymphatic tissue to interact with T
cells and help shape the adaptive anti-tumor immune response. 

The study was a collaborative research effort between Lytix and the research
groups of Dr. Lorenzo Galluzzi at Weill Cornell Medicine, New York and Dr. Joost
Oppenheim at National Cancer Institute, Frederick, both in USA. 


"Establishing the molecular mechanisms through which LTX-315 elicits
tumor-targeting immune responses represents an important step towards realizing
the full translational potential of this oncolytic peptide" Galluzzi said in a
comment.


"These data are very exciting and establish the mechanisms by which LTX-315 both
induces the release of tumor antigens and DC activation, the two critical steps
for generating tumor specific T cells responses The findings further strengthen
the position of LTX-315 as an anticancer immunotherapeutic agents ideal to be
combined with other types of immuno-therapy." said Øystein Rekdal, CEO of Lytix
Biopharma.


The poster can be found here
https://www.lytixbiopharma.com/research-development/posters.html



ABOUT SITC
The Society for Immunotherapy of Cancer (SITC) Annual Meeting & Pre-Conference
Programs brings together stakeholders across the cancer immunotherapy field to
advance the science, discover breakthroughs and educate the world on cancer
immunotherapy.
As the largest conference solely focused on cancer immunotherapy, the Annual
meeting provides international leaders from academia, regulatory and government
agencies, as well as industry representatives with a multidisciplinary
educational and interactive environment focused on improving outcomes for all
cancer patients.


For further information please contact: 
Øystein Rekdal (CEO), 
Telephone: +47 975 73 358 
E-mail: Oystein.Rekdal@lytixbiopharma.com


LYTIX BIOPHARMA IN BRIEF: 
Based in Oslo, Norway, Lytix is a clinical stage biotech company developing
novel cancer immunotherapies, an area within cancer therapy that is aimed at
activating the patient's immune system to fight cancer. The company's technology
is based on pioneering research in "host defense peptides" - nature's first line
of defense towards foreign pathogens. Lytix Biopharma's lead product, LTX-315,
is a first-in-class oncolytic molecule representing a new and superior
therapeutic principle to boost anti-cancer immunity, with the potential to be
the ideal combination partner with other types of immunotherapies. LTX-315
targets cancer cells and disintegrates their cell membranes, causing immunogenic
cell death and release of a patient's tumor specific antigens and potent
immunostimulants. This mode of action allows cytotoxic T cells to recognize,
infiltrate and attack cancer cells.